Prostate Cancer Vaccine Wins OK
A new vaccine called Provenge has just been accepted by the FDA, making it the first to be approved by the agency for men fighting advanced prostate cancer. While Provenge is not a cure, it has shown promise in extending the lives of patients.
The treatment won’t come cheap, however, at $93,000 per patient. –JCL
WAIT, BEFORE YOU GO…
A “vaccine” which harnesses the body’s own immune system to fight prostate cancer has been approved for use by US drug regulators.
Provenge — which is designed to be used in men with advanced disease — is the first of its kind to be accepted by the Food and Drug Administration.
Each dose has to be individually tailored and it is an expensive treatment at $93,000 per patient.
It will add to, rather than replace, existing treatments, said experts.
If you're reading this, you probably already know that non-profit, independent journalism is under threat worldwide. Independent news sites are overshadowed by larger heavily funded mainstream media that inundate us with hype and noise that barely scratch the surface. We believe that our readers deserve to know the full story. Truthdig writers bravely dig beneath the headlines to give you thought-provoking, investigative reporting and analysis that tells you what’s really happening and who’s rolling up their sleeves to do something about it.
Like you, we believe a well-informed public that doesn’t have blind faith in the status quo can help change the world. Your contribution of as little as $5 monthly or $35 annually will make you a groundbreaking member and lays the foundation of our work.